Toca 5 Clinical Trial

Virus Treatment for Brain Cancer: Enrollment is Now Open for Patients with Recurrent Glioblastoma and Anaplastic Astrocytoma

Brain cancers, such as glioblastoma (GBM) and anaplastic astrocytoma (AA), often regrow despite initial treatment. Participation in a clinical trial is one possible option for people who have regrowth of these types of brain cancers. It is recommended that patients talk with their doctor to discuss potential participation in a clinical trial.

Tocagen is developing a cancer-selective virus for the treatment of cancer. The company is conducting a clinical trial, called Toca 5, for patients with recurrent GBM or recurrent AA who are planning to have their tumor removed surgically. Please fill out the Patient Inquiry Form to learn more about potential participation in the Toca 5 trial or call our patient support and liaison Mary Lovely, PhD, RN at (858) 412-8473.

A patient may qualify for this study if the patient:

  • has glioblastoma or anaplastic astrocytoma at 1st or 2nd recurrence (including this recurrence)
  • has had prior surgery, radiation and chemotherapy
  • is between 18 years old and 75 years old

Currently, this study is being offered in the United States, Canada, and Israel. View a list of participating sites.

Learn more about the study including a full list of entry criteria.

Toca 511 & Toca FC are investigational products. An investigational product is one that has not been proven to be safe and effective for this use and is not licensed by the US Food and Drug Administration or any other government agency. An investigational product can only be administered in a research study.